Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs1,2,3 Treatment with Phesgo is over 90% faster, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo™ ...

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, ...

SAN DIEGO, Dec. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission has approved Roche's Phesgo ®, a fixed-dose combination of Perjeta ® ...

Biotechnology pioneer Halozyme has developed ENHANZE, a drug delivery technology that can enable and optimize the subcutaneous (SC) drug delivery of coadministered therapeutics. ENHANZE is based on ...

* Says co has filed a lawsuit and a petition for provisional disposition order against Nippon Kayaku Co.,Ltd, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 ...

Sept. 1, 2005 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., have warned healthcare professionals via letter of study data linking trastuzumab (Herceptin) therapy to a ...